Stoner, Austin
Fu, Li
Nicholson, LaShae
Zheng, Chao
Toyonaga, Takuya
Spurrier, Joshua
Laird, Will
Cai, Zhengxin
Strittmatter, Stephen M.
Funding for this research was provided by:
National Institute on Aging (R01AG034924)
Article History
Received: 25 March 2023
Accepted: 25 October 2023
First Online: 15 November 2023
Declarations
:
: Not applicable.
: Not applicable.
: S.M.S. is an inventor on Yale intellectual property related to PrP<sup>C</sup> as a target for Alzheimer’s therapy. S.M.S. is a Founder, Equity Holder and Director of Allyx Therapeutics seeking to develop mGluR5 directed therapies for AD.